share_log

BRIEF-Virpax Pharmaceuticals Inc To Develop Intranasal Cannabidiol Product To Manage Epilepsy In Adults And Children

BRIEF-Virpax Pharmaceuticals Inc To Develop Intranasal Cannabidiol Product To Manage Epilepsy In Adults And Children

簡報-Virpax製藥公司將開發鼻腔用大麻二醇產品來治療成人和兒童癲癇
reuters ·  2021/09/20 09:30

Sept 20 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :

路透9月20日電-Virpax PharmPharmticals Inc VRPX.O:

* VIRPAX TO DEVELOP INTRANASAL CANNABIDIOL PRODUCT FOR THE MANAGEMENT OF EPILEPSY IN ADULTS AND CHILDREN

*VIRPAX將開發鼻內大麻二醇產品,用於治療成人和兒童癲癇

* VIRPAX - ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS FROM NANOMERICS TO USE NANOMERIC'S MET FOR NASAL DELIVERY OF CBD FOR MANAGEMENT OF EPILEPSY IN ADULTS, CHILDREN

*VIRPAX-從NANOMERICS獲得了使用NANOMERIC的MET進行CBD鼻腔給藥的全球獨家權利,用於治療成人和兒童的癲癇

Source text for Eikon: ID:nBwbHlsyfa Further company coverage: VRPX.O

Eikon的源文本:ID:nBwbHlsyfa進一步的公司報道:VRPX.O

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論